CEFTIN
LOE ApproachingNDAORALFOR SUSPENSION
Approved
Jun 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CEFTIN is an oral cephalosporin antibiotic approved in 1994 for treating bacterial infections across multiple body systems. The drug is formulated as an oral suspension for convenient administration. As a small-molecule beta-lactam antibiotic, it works by inhibiting bacterial cell wall synthesis.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating potential team contraction and shift toward lifecycle management activities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CEFTIN offers limited expansion opportunities given the approaching LOE and zero linked job openings, but provides stable experience in antibiotic portfolio management and generic transition strategies. Career growth potential is constrained; roles focus on operational efficiency and managed decline rather than market growth.
Brand ManagerField Sales Representative
Worked on CEFTIN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.